Navigation Links
GlaxoSmithKline and Cellzome Announce Major Strategic Alliance
Date:9/10/2008

Kinobeads(TM) Technology to Identify a New Generation of Drug Candidates

for Inflammatory Diseases

LONDON and CAMBRIDGE, England and PHILADELPHIA and HEIDELBERG, Germany, September 10 /PRNewswire/ -- Cellzome Inc. and GlaxoSmithKline (LSE & NYSE: GSK) announce the signing of a worldwide strategic alliance to discover, develop and market novel kinase-targeted therapeutics to treat inflammatory diseases.

The alliance gives GSK access to Cellzome's significant expertise in identifying and developing selective kinase inhibitors and its proprietary Kinobeads(TM) technology which, by screening compounds in a physiological setting, is designed to improve the predictability of these drug candidates' performance in clinical testing. Kinases are key molecular switches in cellular signaling events with a central role in many inflammatory responses and selective inhibitors offer a different approach to therapeutic intervention in diseases such as rheumatoid arthritis or multiple sclerosis.

Under the agreement GSK has exclusive options to license drug candidates from Cellzome's kinase programs directed against four identified targets, and three additional targets to be jointly identified by both parties. In the alliance, Cellzome will utilize its proprietary Kinobeads(TM) technology to discover novel small molecule inhibitors of these targets, and then will develop the most promising product candidates through to completion of a clinical proof of concept trial, unless GSK elects to exercise its option earlier. Cellzome is eligible to receive success-based milestones from GSK as product candidates are advanced. Upon Cellzome's achievement of clinical proof of concept for a product candidate for a particular kinase target, GSK would have an exclusive option to license all product candidates from that program. GSK would then assume full responsibility for further clinical development and commercialization on a worldwide basis. Ce
'/>"/>

SOURCE Cellzome Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GlaxoSmithKline Offers New Purchasing Options to Help Employers Overcome Barriers to Pandemic Stockpiling of Relenza(R)
2. GlaxoSmithKline To Post Quarterly US Grants Report
3. GlaxoSmithKline - Q2 Results and Strategy Update - Interview with CEO
4. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
5. CDC Immunization Advisory Committee Recommends Two New Pediatric Vaccines from GlaxoSmithKline
6. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
7. GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections
8. GlaxoSmithKline Signs Licensing Agreement With Compendia Bioscience
9. GlaxoSmithKline Named A Top Employer for Promoting Healthy Lifestyles
10. GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
11. GlaxoSmithKline to Acquire Sirtris Pharmaceuticals, a World Leader in Sirtuin Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... MENLO PARK, Calif. , Oct. 20, 2014 ... announced today that the Company has signed a ... Institute of Regenerative Medicine (CIRM), effective October 1, ... of Clinical Development payments and the release of ... $14.3 million CIRM grant award for clinical development ...
(Date:10/20/2014)... BOSTON , Oct. 20, 2014 ... commercialization company tackling big healthcare problems, announced today ... investment round, with participation from Invesco Perpetual, a ... be used to drive PureTech,s existing pipeline forward ... technologies. "PureTech has the scientific creativity to really ...
(Date:10/19/2014)... October 19, 2014 The Latin American ... market in Latin America with analysis and forecast of ... 2013, and is expected to reach $2,366.8 million by ... 2018. , Browse through the TOC of the Latin ... of the in-depth analysis provided. It also provides a ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 The Asian ... in Asian with analysis and forecast of revenue. The ... grow to around $463.9 million by 2018, at a ... Browse through the TOC of the Asian Automatic patient ... analysis provided. This also provides a glimpse of the ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3
... engineering research at the University of Pennsylvania demonstrates ... to nanoscale semiconductors. This represents a promising advance ... circuits that use light rather than electricity. ... Agarwal, postdoctoral fellow Lambert van Vugt and graduate ...
... Inc. (NYSE Amex: PIP ), a biodefense ... announced today that it has completed a previously announced ... of approximately $6.5 million. Under the terms ... 1,857,143 units to certain institutional investors for a purchase ...
... ("NeoStem" or the "Company") (NYSE Amex: NBS ... revenues, global research and development capabilities and operations in ... China adult stem cells, and China pharmaceuticals, announced today ... will present at the Proactive Investors One2One Investor Forum ...
Cached Biology Technology:Penn researchers break light-matter coupling strength limit in nanoscale semiconductors 2Penn researchers break light-matter coupling strength limit in nanoscale semiconductors 3PharmAthene Completes $6.5 Million Registered Direct Offering 2PharmAthene Completes $6.5 Million Registered Direct Offering 3NeoStem to Present at Two Investor Events This Month 2NeoStem to Present at Two Investor Events This Month 3NeoStem to Present at Two Investor Events This Month 4
(Date:10/22/2014)... 2014 The Nano-Bio Manufacturing Consortium (NBMC), an ... Laboratory (AFRL), has chosen a project proposed by the ... of Arizona College of Medicine – Tucson ... goal is to assess different sweat collection methods and ... sweat under a variety of human-body conditions, the results ...
(Date:10/18/2014)... and stress-related psychiatric disorders are associated with ... molecular mechanisms underlying this relation are unknown. ... development of targeted preventive strategies and new ... This work is presented at the European ... an international group of researchers from Germany ...
(Date:10/17/2014)... . Why do ... to reproduce? And why are there two sexes anyway? These ... of the research journal Molecular Human Reproduction published ... Bielefeld University Bielefeld has compiled this special issue on sperm ... to copulate with several males in quick succession – chimpanzees ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3Researchers find why depression and aging linked to increased disease risk 2Sperm wars 2
... present its fourth annual Regional Policy Award to Karen Hixon ... Society,s 96th Annual Meeting on Sunday August 7 in Austin, ... who has an outstanding record of informing political decision-making with ... Parks and Wildlife Commission by Governor Rick Perry in 2007 ...
... network of researchers will evaluate potential harmful effects ... birth outcomes, the cardiorespiratory system, and behavior and ... partnerships, under the leadership of NIH,s National Institute ... to evaluate the level of potentially harmful contaminants ...
... GALVESTON, Texas In an effort to determine the ... BP oil spill,the National Institute of Environmental Health Sciences ... consortium of university researchers and Gulf Coast community groups ... Galveston to examine the safety of Gulf seafood and ...
Cached Biology News:Texas Parks Wildlife Commission member Karen Hixon to receive ESA's 2011 Regional Policy Award 2NIH-funded research network to explore oil spill health effects 2UTMB-led researchers awarded $7.8 million for Gulf spill study 2UTMB-led researchers awarded $7.8 million for Gulf spill study 3
...
Pronase Reagent...
Rabbit polyclonal to ECSIT ( Abpromise for all tested applications). entrezGeneID: 51295 SwissProtID: Q96HQ7...
Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide...
Biology Products: